Industrializing iPSC and Harnessing its Medical Applications – An Interview with Dr. Hong-Lin Su
Featured in the special topic of Gene and Cell Therapy, GeneOnline is honored to interview Professor Hong-Lin Su from the Department of Life Sciences at National Chung Hsing University, who is one of the few induced pluripotent stem cell (iPSC) experts in the field of cell therapy in Taiwan, with experience in academia, industry, and clinical practice.
The technology of neural differentiation from pluripotent stem cells developed by Prof. Su’s team not only won the National Innovation Award in 2017 but was also successfully patented in Taiwan, the US, and Japan. During the interview, Prof. Su introduced the principle of iPS cell therapy and its current clinical applications. He also shared his rich experience accelerating the formation of Taiwan's cell therapy industry chain by establishing DuoGenic Stem Cells in recent years.
The technology of neural differentiation from pluripotent stem cells developed by Prof. Su’s team not only won the National Innovation Award in 2017 but was also successfully patented in Taiwan, the US, and Japan. During the interview, Prof. Su introduced the principle of iPS cell therapy and its current clinical applications. He also shared his rich experience accelerating the formation of Taiwan's cell therapy industry chain by establishing DuoGenic Stem Cells in recent years.
It's free! Log in now to read
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02